DrugPatentWatch Database Preview
Patent: 10,338,039
» See Plans and Pricing
Summary for Patent: 10,338,039
| Title: | Method for detecting monoclonal antibody using mass spectrometry |
| Abstract: | A method is provided for more easily detecting and quantifying a protein by regioselectively digesting a variable region of an Fab domain of a monoclonal antibody while suppressing proteolysis of an Fc domain. In the method, a porous body in which a monoclonal antibody is immobilized in pores and nanoparticles on which a protease is immobilized are brought into contact with each other in a liquid to perform selective proteolysis of the monoclonal antibody, and a resulting peptide fragment is detected using liquid chromatography-mass spectrometry (LC-MS), and a peptide having an amino acid sequence that includes an amino acid derived from a CDR2 region of a heavy chain or a light chain of the monoclonal antibody is detected. |
| Inventor(s): | Shimada; Takashi (Kyoto, JP), Iwamoto; Noriko (Kyoto, JP) |
| Assignee: | SHIMADZU CORPORATION (Kyoto-shi, JP) |
| Application Number: | 15/556,018 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,338,039
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | HERCEPTIN HYLECTA | trastuzumab; hyaluronidase-oysk | INJECTABLE;SUBCUTANEOUS | 761106 | 001 | 2019-02-28 | Start Trial | SHIMADZU CORPORATION (Kyoto-shi, JP) | 2035-03-09 | RX | search | |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 002 | 2017-06-22 | Start Trial | SHIMADZU CORPORATION (Kyoto-shi, JP) | 2035-03-09 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | SHIMADZU CORPORATION (Kyoto-shi, JP) | 2035-03-09 | RX | Orphan | search |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 002 | 2004-02-26 | Start Trial | SHIMADZU CORPORATION (Kyoto-shi, JP) | 2035-03-09 | RX | search | |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | SHIMADZU CORPORATION (Kyoto-shi, JP) | 2035-03-09 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 10,338,039
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2016143224 | Start Trial |
| United States of America | 2018059074 | Start Trial |
| Singapore | 11201707318P | Start Trial |
| South Korea | 102000862 | Start Trial |
| South Korea | 20170121265 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
